Samsung Pharm - Asset Resilience Ratio

Latest as of September 2025: 6.69%

Samsung Pharm (001360) has an Asset Resilience Ratio of 6.69% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Also explore Samsung Pharm asset portfolio for the complete picture of this company's asset base.

Liquid Assets

₩15.00 Billion

≈ $10.17 Million USD Cash + Short-term Investments

Total Assets

₩224.14 Billion

≈ $151.89 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2015–2024)

This chart shows how Samsung Pharm's Asset Resilience Ratio has changed over time. See Samsung Pharm (001360) balance sheet quality index to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Samsung Pharm's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Samsung Pharm market capitalisation.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	₩0.00	0%
Short-term Investments	₩15.00 Billion	6.69%
Total Liquid Assets	₩15.00 Billion	6.69%

Asset Resilience Insights

Limited Liquidity: Samsung Pharm maintains only 6.69% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Samsung Pharm Industry Peers by Asset Resilience Ratio

Compare Samsung Pharm's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Takeda Pharmaceutical Co Ltd ADR NYSE:TAK	Drug Manufacturers - Specialty & Generic	4.94%
Jiangsu Hengrui Medicine Co Ltd SHG:600276	Drug Manufacturers - Specialty & Generic	0.16%
Takeda Pharmaceutical Company Limited F:TKDA	Drug Manufacturers - Specialty & Generic	0.69%
Ajanta Pharma Limited NSE:AJANTPHARM	Drug Manufacturers - Specialty & Generic	14.99%
Kangmei Pharmaceutical Co Ltd SHG:600518	Drug Manufacturers - Specialty & Generic	0.00%
Cronos Group Inc TO:CRON	Drug Manufacturers - Specialty & Generic	69.94%
Guizhou Bailing Group Pharmaceutical Co Ltd SHE:002424	Drug Manufacturers - Specialty & Generic	2.09%
Dezhan HealthCare Co Ltd SHE:000813	Drug Manufacturers - Specialty & Generic	0.15%

Annual Asset Resilience Ratio for Samsung Pharm (2015–2024)

The table below shows the annual Asset Resilience Ratio data for Samsung Pharm.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	2.34%	₩3.00 Billion ≈ $2.03 Million	₩128.45 Billion ≈ $87.05 Million	-14.63pp
2022-12-31	16.96%	₩20.00 Billion ≈ $13.55 Million	₩117.91 Billion ≈ $79.91 Million	-9.37pp
2021-12-31	26.33%	₩38.30 Billion ≈ $25.96 Million	₩145.46 Billion ≈ $98.57 Million	+24.89pp
2020-12-31	1.45%	₩2.59 Billion ≈ $1.75 Million	₩178.73 Billion ≈ $121.12 Million	-14.58pp
2019-12-31	16.03%	₩27.02 Billion ≈ $18.31 Million	₩168.53 Billion ≈ $114.21 Million	-10.47pp
2018-12-31	26.50%	₩42.57 Billion ≈ $28.85 Million	₩160.65 Billion ≈ $108.87 Million	+8.42pp
2017-12-31	18.08%	₩27.88 Billion ≈ $18.89 Million	₩154.19 Billion ≈ $104.50 Million	+13.01pp
2016-12-31	5.08%	₩7.02 Billion ≈ $4.76 Million	₩138.28 Billion ≈ $93.71 Million	-4.91pp
2015-12-31	9.99%	₩13.01 Billion ≈ $8.81 Million	₩130.22 Billion ≈ $88.25 Million	--

pp = percentage points

About Samsung Pharm

KO:001360 Korea Drug Manufacturers - Specialty & Generic

Market Cap

$103.33 Million

₩152.47 Billion KRW

Market Cap Rank

#19167 Global

#985 in Korea

Share Price

₩1620.00

Change (1 day)

+0.00%

52-Week Range

₩1343.00 - ₩2210.00

All Time High

₩12289.83